Almirall and absci announce ai drug discovery partnership to rapidly develop novel treatments for dermatological diseases

Barcelona, spain & vancouver, wash.--(business wire)--almirall s.a. (bme: alm), a global biopharmaceutical company focused on medical dermatology, and absci corporation (nasdaq: absi), a generative ai drug creation company, today announced a drug discovery partnership aimed to develop and commercialize ai-designed therapeutics to fight chronic and debilitating dermatological diseases. the partnership combines absci's integrated drug creation™ platform with almirall's dermatological expertise wi.
ABSI Ratings Summary
ABSI Quant Ranking